Loading
Life sciences · Journal article
Scientific Reports · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The global increase in carbapenem-resistant Klebsiella pneumoniae (CRKP) has undoubtedly changed the management of infectious diseases. Meropenem resistance in K. pneumoniae is a response to bacterial strategies, these includes production of carbapenemases (KPC, NDM, OXA-48), a reduction in membrane permeability through mutation of porin (OmpK35/36), and genomic plasticity via gene amplification and/or plasmid exchange. This study developed a machine learning model that targets “Very Major Errors” (VMEs) and predicts antimicrobial resistance (AMR) for prognosis. Genomic datasets (6000) were retrieved from the Bacterial and Viral Bioinformatics Resource Center (BV-BRC) database and preprocessed. Gene-based feature engineering was performed using Kleborate, and a Random Forest model was trained and deployed via an interactive R Shiny web application. Internal validation of the tool PredKlebAMR was done using a stratified 80/20 split of the training dataset, and a 5-fold cross-validation was implemented to optimize the Random Forest hyperparameters. While benchmarking against ResFinder 4.1 and AMRFinderPlus 4.2.7 was done using an independent external cohort consisting of three-tiered datasets from the National Center for Biotechnology Information (NCBI) database. PredKlebAMR, trained using 5,942 K. pneumoniae genomes (38 Kleborate-derived predictors), achieved a strong performance on a held-out global test set (accuracy 91.92%, sensitivity 94.67%, specificity 89.47%; Kappa 0.839), with key predictors including fluoroquinolone mutations, high-risk sequence types, KPC-2/KPC-3, and OmpK35/36 porin changes. When benchmarked against AMRFinderPlus 4.2.7 and ResFinder 4.1, PredKlebAMR delivered a higher sensitivity and fewer VMEs in the global cohort (95.45% vs 90.91% | 86.36% sensitivity; VMEs 1 vs 2 | 3), the African cohort (95.56% vs 91.11% | 82.2% sensitivity; VMEs 2 vs 4 | 8), and the Thailand cohort (95.62% vs 92.5% | 63.12% sensitivity; VMEs 7 vs 12 | 59) with statistically significant sensitivity improvement in Africa (McNemar’s p = 0.041). PredKlebAMR, with its high sensitivity to VMEs, and via an interactive dashboard ( https://igmr.org/software/predklebamr ) that translates predictions into biological rationale, will support clinicians in making life-changing decisions while managing patients.